Heron Therapeutics, Inc.
General ticker "HRTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $232.1M (TTM average)
Heron Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -23.1%.
Estimated limits based on current volatility of 5.3%: low 0.43$, high 0.48$
Factors to consider:
- Total employees count: 128 (+4.9%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Market acceptance, Reimbursement risks, Supply chain disruptions, Regulatory and compliance, Capital raising failure
- Current price 36.5% below estimated low
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.74$, 2.11$]
- 2026-12-31 to 2027-12-31 estimated range: [1.04$, 2.66$]
Financial Metrics affecting the HRTX estimates:
- Positive: with PPE of -16.2 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Positive: -5.34 < Operating profit margin, % of -1.61
- Positive: Investing cash flow per share per price, % of 7.39 > -0.60
Short-term HRTX quotes
Long-term HRTX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $127.04MM | $144.28MM | $154.90MM |
| Operating Expenses | $237.66MM | $155.81MM | $157.44MM |
| Operating Income | $-110.61MM | $-11.53MM | $-2.54MM |
| Non-Operating Income | $0.06MM | $-2.05MM | $-17.66MM |
| Interest Expense | $3.87MM | $6.03MM | $9.61MM |
| R&D Expense | $39.13MM | $16.68MM | $12.43MM |
| Income(Loss) | $-110.56MM | $-13.58MM | $-20.20MM |
| Net Income(Loss)* | $-110.56MM | $-13.58MM | $-20.20MM |
| Stockholders Equity | $-33.97MM | $-33.65MM | $14.33MM |
| Inventory | $42.11MM | $53.16MM | $92.75MM |
| Assets | $222.51MM | $233.15MM | $255.88MM |
| Operating Cash Flow | $-58.79MM | $-22.53MM | $-27.59MM |
| Capital expenditure | $1.54MM | $1.71MM | $0.32MM |
| Investing Cash Flow | $18.00MM | $18.71MM | $16.01MM |
| Financing Cash Flow | $54.11MM | $0.94MM | $14.43MM |
| Earnings Per Share** | $-0.80 | $-0.09 | $-0.12 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.